ArticleFrontiers in immunology2021
Radiation Augments the Local Anti-Tumor Effect of
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors.bioRxiv : the preprint server for biology · 2026Article
- Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice.Journal for immunotherapy of cancer · 2025Article
- Enhancing Anti-PD-1 Immunotherapy by Targeting MDSCs via Hepatic Arterial Infusion in Breast Cancer Liver Metastases.Cancers · 2024Article
- A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).Oncology reports · 2024Review
- Immunologic tumor microenvironment modulators for turning cold tumors hot.Cancer communications (London, England) · 2024Review
- An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.Future oncology (London, England) · 2024Article
- Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.Journal of translational medicine · 2023Article
- Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.Cancer immunology, immunotherapy : CII · 2023Article
- Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.Breast cancer research : BCR · 2023Article
- Article
- Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.Journal for immunotherapy of cancer · 2023Article
- Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody.Biomaterials research · 2022Article
- Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Alexander A PieperDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Luke M ZanglDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Dan V SpeigelmanDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Arika S FeilsDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Anna HoefgesDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Justin C JagodinskyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Mildred A FelderDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Noah W TsarovskyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Ian S ArthurDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Ryan J BrownDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Jen BirstlerDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Trang LeDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Peter M CarlsonDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Amber M BatesDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Jacquelyn A HankDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Alexander L RakhmilevichDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Paul M SondelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Ravi B PatelDepartment of Radiation Oncology and Bioengineering, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, United States.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
University of Wisconsin–Madison · USUPMC Hillman Cancer Center · US
Funding
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MRadionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2020 to 2024
$12.5MProject 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8MNRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4MIntegrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MUtilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sitesK08CA241319 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PATEL, RAVI BHASKER · 2019 to 2023
$629kMolecular targeted radiotherapy to overcome resistance to in situ cancer vaccinationF30CA228315 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSON, PETER M · 2019 to 2021
$102kBrachytherapy to achieve in situ cancer vaccinationF30CA250263 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI JAGODINSKY, JUSTIN CHARLES · 2021 to 2023
$96kNCATS NIH HHS TL1 TR002375NCATS NIH HHS UL1 TR002373NCI NIH HHS F30 CA228315NCI NIH HHS F30 CA250263NCI NIH HHS K08 CA241319NCI NIH HHS P01 CA250972NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NIDCR NIH HHS P50 DE026787NIGMS NIH HHS T32 GM140935NIH HHS DP5 OD024576
Abstract
Introduction: Combining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective Methods: Mice bearing flank tumors (A20 lymphoma, B78 melanoma or 4T1 breast cancer) were treated with combinations of local RT, CpG, and/or OX40, and response to treatment was monitored. Flow cytometry and quantitative polymerase chain reaction (qPCR) experiments were conducted to study differences in the TME, secondary lymphoid organs, and immune activation after treatment. Results: An Conclusion: RT significantly improves the local anti-tumor effect of the
Indexed as
AnimalsCancer VaccinesCell Line, TumorCombined Modality TherapyDisease Models, AnimalFemaleLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalOligodeoxyribonucleotidesReceptors, OX40T-Lymphocytes, RegulatoryTumor MicroenvironmentCancer VaccinesCPG-oligonucleotideOligodeoxyribonucleotidesReceptors, OX40cold tumor modelsCpG – oligonucleotidesIn situ vaccineOX40 agonistradiation therapyradioimmunotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.